Biotech Bearish Stocks: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), Endocyte (NASDAQ:ECYT), CytRx Corporation (NASDAQ:CYTR)

Posted by on Jul 09, 2014

On June 19, 2014, Novavax, Inc. (NASDAQ:NVAX), announced a number of promotions within its management team. John A. Herrmann III, J.D. has been named Senior Vice President, General Counsel and Corporate Secretary. Denise Courbron, M.S., PMP has been named Vice President, Global Program Management to lead Novavax’ program management efforts covering all vaccine development programs. Novavax, Inc. (NASDAQ:NVAX), weekly performance is -6.06%. On last trading day company shares ended up $4.34. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is -4.05%.

On July 01, 2014, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), announced that it has been added to the Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), fell 5.99% in last trading session and ended the day on $6.90. ACHN, return on assets is -37.40%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), quarterly performance is 129.24%.

Endocyte, Inc. (NASDAQ:ECYT), was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Monday. The firm currently has a $7.90 price objective on the stock. Zacks‘s target price would suggest a potential upside of 17.91% from the stock’s previous close. Endocyte, Inc. (NASDAQ:ECYT), shares moved down 5.73% in last trading session and was closed at $6.25, while trading in range of $6.22 – 6.74 Endocyte, Inc. (NASDAQ:ECYT), year to date (YTD) performance is -41.48%.

On June 30, 2014, CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced that it was added to the Russell 3000® and Russell 2000® Indexes when the Russell Investment Group reconstituted its family of U.S. indexes after the stock market close on June 27, 2014. CytRx Corporation (NASDAQ:CYTR), ended the last trading day at $3.68. Company weekly volatility is calculated as 4.95% and price to cash ratio as 1.82. CytRx Corporation (NASDAQ:CYTR), showed a negative weekly performance of 11.96%.

Leave a Reply

Your email address will not be published. Required fields are marked *